12/4
04:25 pm
lly
Eli Lilly and Company (NYSE:LLY) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Low
Report
Eli Lilly and Company (NYSE:LLY) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
12/4
11:51 am
lly
Eli Lilly and Company (LLY): A Bull Case Theory [Yahoo! Finance]
Low
Report
Eli Lilly and Company (LLY): A Bull Case Theory [Yahoo! Finance]
12/4
09:03 am
lly
Eli Lilly and Company (NYSE:LLY) was given a new $1,200.00 price target on by analysts at BMO Capital Markets.
Low
Report
Eli Lilly and Company (NYSE:LLY) was given a new $1,200.00 price target on by analysts at BMO Capital Markets.
12/3
03:08 pm
lly
Companies Cut Prices For Blockbuster Weight-Loss Drugs [Forbes]
Low
Report
Companies Cut Prices For Blockbuster Weight-Loss Drugs [Forbes]
12/3
02:08 pm
lly
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor [Yahoo! Finance]
Low
Report
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor [Yahoo! Finance]
12/3
12:59 pm
lly
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
Low
Report
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
12/3
09:54 am
lly
Tech Is Getting Left Behind in the S&P 500's Latest Rebound [Yahoo! Finance]
Low
Report
Tech Is Getting Left Behind in the S&P 500's Latest Rebound [Yahoo! Finance]
12/3
09:39 am
lly
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Wolfe Research from $1,050.00 to $1,250.00. They now have an "outperform" rating on the stock.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Wolfe Research from $1,050.00 to $1,250.00. They now have an "outperform" rating on the stock.
12/3
08:05 am
lly
Eli Lilly and Company (NYSE:LLY) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/2
05:27 pm
lly
Eli Lilly Canada: Everyone has a critical role at Eli Lilly Canada [Globe and Mail, The (Toronto, Canada)]
Low
Report
Eli Lilly Canada: Everyone has a critical role at Eli Lilly Canada [Globe and Mail, The (Toronto, Canada)]
12/2
11:13 am
lly
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
12/2
09:41 am
lly
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Berenberg Bank from $830.00 to $950.00. They now have a "hold" rating on the stock.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Berenberg Bank from $830.00 to $950.00. They now have a "hold" rating on the stock.
12/2
08:17 am
lly
Forbes Daily: Gen Z Leaders Now Dominate The Forbes 30 Under 30 [Forbes]
Low
Report
Forbes Daily: Gen Z Leaders Now Dominate The Forbes 30 Under 30 [Forbes]
12/2
01:16 am
lly
Morgan Stanley Bullish on Eli Lilly and Company (LLY) [Yahoo! Finance]
Low
Report
Morgan Stanley Bullish on Eli Lilly and Company (LLY) [Yahoo! Finance]
12/1
05:02 pm
lly
Eli Lilly and Company (NYSE:LLY) was given a new $1,286.00 price target on by analysts at National Bankshares, Inc..
Low
Report
Eli Lilly and Company (NYSE:LLY) was given a new $1,286.00 price target on by analysts at National Bankshares, Inc..
12/1
03:55 pm
lly
Eli Lilly cuts cash prices on single dose vials of weight-loss drug Zepbound [CNBC]
Low
Report
Eli Lilly cuts cash prices on single dose vials of weight-loss drug Zepbound [CNBC]
12/1
03:27 pm
lly
Eli Lilly Cuts Cash Prices for Zepbound Vials on LillyDirect [Yahoo! Finance]
Low
Report
Eli Lilly Cuts Cash Prices for Zepbound Vials on LillyDirect [Yahoo! Finance]
12/1
02:03 pm
lly
Lilly Endowment Awards $400+ Million To Colleges, Theological Schools [Forbes]
Low
Report
Lilly Endowment Awards $400+ Million To Colleges, Theological Schools [Forbes]
12/1
01:54 pm
lly
Eli Lilly cuts Zepbound prices in competitive weight loss drug market battle [FOX Business Network]
Low
Report
Eli Lilly cuts Zepbound prices in competitive weight loss drug market battle [FOX Business Network]
12/1
11:04 am
lly
Eli Lilly and Company (NYSE:LLY) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
12/1
10:13 am
lly
Eli Lilly cuts cash price for Zepbound weight loss drug vials [Yahoo! Finance]
Low
Report
Eli Lilly cuts cash price for Zepbound weight loss drug vials [Yahoo! Finance]
12/1
09:52 am
lly
Eli Lilly Lowers Weight-Loss Drug Zepbound Prices After Trump Deal [Forbes]
Low
Report
Eli Lilly Lowers Weight-Loss Drug Zepbound Prices After Trump Deal [Forbes]
12/1
08:36 am
lly
Eli Lilly cuts price for popular weight-loss drug Zepbound [Yahoo! Finance]
Low
Report
Eli Lilly cuts price for popular weight-loss drug Zepbound [Yahoo! Finance]
12/1
08:36 am
lly
Eli Lilly cuts price for popular weight-loss drug Zepbound [USA TODAY]
Low
Report
Eli Lilly cuts price for popular weight-loss drug Zepbound [USA TODAY]
12/1
08:10 am
lly
Eli Lilly cuts Zepbound price to widen access for obesity drug [Yahoo! Finance]
Low
Report
Eli Lilly cuts Zepbound price to widen access for obesity drug [Yahoo! Finance]